Oncology Brothers: Practice-Changing Cancer Discussions
Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)
· 23 min
Episodebeskrivelse
In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.
Key topics discussed included:
The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies
The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma
Treatment selection based on patient age, prior therapy, drug exposure, and disease biology
The importance of shared decision-making and incorporating patient preferences into treatment planning
Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care
This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
X/Twitter: https://x.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology.
#MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology
Nettsted: infoaj7.podbean.com
